Progenra, Inc.
- Biotech or pharma, therapeutic R&D
Progenra is one of the leaders in the field of targeted protein degradation (TPD), driving innovation to restore mitochondrial health in neurodegenerative diseases. Our lead molecular glue program targets the PINK1 kinase–parkin E3 ligase pathway to repair damaged mitochondria in Parkinson’s disease (PD). This first-in-class candidate demonstrates exceptional potency—over 20 times more active than AbbVie’s clinical-stage molecule—and has shown robust efficacy in preclinical studies. Beyond PD, Progenra’s pipeline includes next-generation degraders of tau aggregates for Alzheimer’s disease, expanding our reach into other critical neurodegenerative indications. Leveraging our deep expertise in the ubiquitin-proteasome system, we are also advancing early-stage programs aimed at anti-aging, muscle regeneration, and cardioprotection.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}